CDMA Disease Briefs

Overview

This reference site contains disease briefs for pig diseases prioritized through a multi-criteria decision analysis (MCDA) process. Each disease has been systematically evaluated across 12 criteria to support research and investment decision-making.

Disease Briefs

Click on any disease below to view its full assessment:

African Swine Fever (ASF)

A highly consequential viral disease with severe hemorrhagic presentation and major transboundary implications.
View Disease Brief →

Porcine Astrovirus

Widely distributed enteric virus, typically subclinical but can cause neurologic disease in piglets.
View Disease Brief →

Vesicular Exanthema of Swine Virus (VESV)

Eradicated vesicular disease clinically indistinguishable from FMD, with marine reservoir risk.
View Disease Brief →

Porcine Norovirus

Genetically diverse calicivirus, typically subclinical with unclear disease role.
View Disease Brief →

Porcine Sapovirus

Common enteric calicivirus associated with mild, self-limiting diarrhea.
View Disease Brief →

Saint Valerien Calicivirus (Valovirus)

Recently described calicivirus with unknown clinical significance.
View Disease Brief →

Evaluation Criteria

Each disease is evaluated across 12 standardized criteria:

  1. Foodborne Zoonotic Transmission Potential
  2. Non-Foodborne Zoonotic Transmission Potential
  3. Transmission via External Non-Farm Pathways
  4. Ability to Detect and Confirm Infection
  5. Financial Impact on Cost of Production
  6. Effect on Domestic or Export Markets
  7. AMR Hazard (Pathogen Propensity)
  8. AMR Selection Pressure (Antimicrobial Use)
  9. Availability of Effective Treatment Options
  10. Availability of Effective Vaccines or Bacterins
  11. Containability of Disease Spread
  12. Eradicability

For detailed criteria definitions, see Criteria & Levels.

Purpose

This MCDA framework supports systematic prioritization of pig diseases for research investment by providing:

  • Transparent evaluation across standardized criteria
  • Consistent scoring using defined level scales
  • Evidence-based justifications for each assessment
  • Comparable profiles across diverse disease threats

Using This Resource

  • Committee members: Review disease briefs before scoring sessions
  • Researchers: Access standardized disease profiles and evidence summaries
  • Decision makers: Compare diseases systematically using MCDA outputs

For background on the MCDA approach and scope, see Definitions & Scope.